{
    "ticker": "MNKTQ",
    "name": "MannKind Corporation",
    "description": "MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products for patients with diabetes and other endocrine disorders. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind is best known for its flagship product, Afrezza, an inhalable insulin that offers a unique and convenient alternative for diabetes management. Afrezza is designed to provide rapid control of blood sugar levels while minimizing the risk of hypoglycemia, addressing a significant unmet need in diabetes care. The company's proprietary Technosphere\u00ae platform enables the delivery of pharmaceutical compounds via inhalation, paving the way for future products that could revolutionize treatment options for various diseases. MannKind's mission is to improve the quality of life for people with diabetes through innovative therapies that enhance patient adherence and outcomes. With a strong focus on research and development, MannKind continues to explore potential applications of its technology in other therapeutic areas, aiming to expand its product portfolio and reach more patients in need.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Danbury, Connecticut, USA",
    "founded": "1991",
    "website": "https://www.mannkindcorp.com",
    "ceo": "Michael Castagna",
    "social_media": {
        "twitter": "https://twitter.com/MannKindCorp",
        "linkedin": "https://www.linkedin.com/company/mannkind-corporation/"
    },
    "investor_relations": "https://www.mannkindcorp.com/investors",
    "key_executives": [
        {
            "name": "Michael Castagna",
            "position": "CEO"
        },
        {
            "name": "Cheryl Blanchard",
            "position": "President and COO"
        }
    ],
    "product_categories": [
        {
            "category": "Diabetes Management",
            "products": [
                "Afrezza"
            ]
        }
    ],
    "seo": {
        "meta_title": "MannKind Corporation | Innovative Diabetes Solutions",
        "meta_description": "Explore MannKind Corporation, a leader in biopharmaceuticals, dedicated to improving diabetes management with innovative inhalable insulin products like Afrezza.",
        "keywords": [
            "MannKind",
            "Afrezza",
            "Diabetes",
            "Inhaled Insulin",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is MannKind known for?",
            "answer": "MannKind is known for its innovative inhalable insulin product, Afrezza, designed for diabetes management."
        },
        {
            "question": "Who is the CEO of MannKind?",
            "answer": "Michael Castagna is the CEO of MannKind Corporation."
        },
        {
            "question": "Where is MannKind headquartered?",
            "answer": "MannKind is headquartered in Danbury, Connecticut, USA."
        },
        {
            "question": "What are MannKind's main products?",
            "answer": "MannKind's main product is Afrezza, an inhalable insulin for diabetes treatment."
        },
        {
            "question": "When was MannKind founded?",
            "answer": "MannKind was founded in 1991."
        }
    ],
    "competitors": [
        "PFE",
        "NVDA",
        "MRNA",
        "AMGN"
    ],
    "related_stocks": [
        "JNJ",
        "GILD",
        "ABBV",
        "BMY"
    ]
}